An Integrated Multiplexed Electrochemical Platform for the Selective Detection of Viral Protein and RNA to Differentiate Active HIV-1 Infection from Vaccine Induced Seropositivity
Award Notice Posted
- Solicitation number
- 75N93022C00031
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Vitruvian Bio, LLC
- Set-aside
- Total Small Business
Opportunity facts
- Contract number
- 75N93022C00031 Federal contract award
- Place of performance
- Ellicott City, Maryland 21043, United States
Notice details come from SAM.gov. Updated .
About this opportunity
Vitruvian Bio, LLC was awarded a $300,000 contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases to develop an integrated multiplexed electrochemical platform that can selectively detect viral protein and RNA to differentiate between active HIV-1 infection and vaccine-induced seropositivity over the course of the contract period ending July 1, 2022. This small business set-aside award will support Vitruvian Bio's efforts to create a detection method distinguishing genuine HIV infection from immunity generated by vaccination for the NIH NIAID.
Notice text
Awarded contract 75N93022C00031 to Vitruvian Bio, LLC for 300000.00 on 2022-07-01.
Notice history
6 of 8 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity